Sorafenib (Nexavar®) is a multi-tyrosine kinase inhibitor that decreases tumor growth and disrupts tumor microvasculature through inhibition of multiple targets including the VGEF receptors VEGFR-1, VEGFR-2 and VEGFR-3 as well as Raf serine/threonine kinases and platelet-derived growth factor receptor β (PDGFR) [73]. This evidence concerns the gene KDR and neoplasm.